ProCE Banner Activity

ALCYONE 3-Yr Follow-up: Daratumumab Plus VMP vs VMP Alone in Newly Diagnosed, Transplantation-Ineligible Myeloma

Slideset Download
Conference Coverage
Daratumumab plus VMP demonstrates significant PFS, OS improvements vs VMP alone in transplantation-ineligible patients with newly diagnosed multiple myeloma.

Released: December 15, 2019

Expiration: December 13, 2020

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company